Hot Natural Products & Bioactive Compounds
BioCrick offers high-purity natural products and bioactive compounds for scientific research. Our natural product collection includes compounds derived from plants, microorganisms and other biological sources and is widely used in pharmacological, biochemical and drug discovery research.
Natural products remain an important source of bioactive molecules and drug leads. BioCrick provides researchers with high-quality natural product compounds together with catalog numbers, product information and biological activity data.
Hot Products from BioCrick
Showing 3417 - 3424 of 9359 hot products
| Catalog No. | Product Name |
|---|---|
| BCC7991 | TC-G 1000 |
|
Potent and selective <span class='symbol'>α</span><sub>2D</sub>-adrenoceptor agonist (K<sub>i</sub> values are 8.6 pM and 110 nM for rat <span class='symbol'>α</span><sub>2D</sub> and <span class='symbol'>α</span><sub>1</sub> receptors respectively and 25, 26 and 100 nM for human <span class='symbol'>α</span><sub>2A</sub>, <span class='symbol'>α</span><sub>2C</sub> and <span class='symbol'>α</span><sub>2B</sub> receptors respectively. Exhibits analgesic activity in a mouse model of abdominal irritation. Orally active.
|
|
| BCC7992 | Necrosulfonamide |
|
Necroptosis inhibitor. Blocks mixed lineage kinase domain-like protein (MLKL), a critical substrate of receptor-interacting serine-threonine kinase 3 (RIP3) during necrosis. Prevents MLKL-RIP1-RIP3 necrosome complex from interacting with downstream necrosis effectors.
|
|
| BCC7993 | BCH |
|
Inhibitor of L-type amino acid transporter LAT1. Suppresses growth and induces apoptosis via activation of caspases in KB, Saos2 and C6 cancer cell lines.
|
|
| BCC7994 | CHC |
|
Monocarboxylic acid transport (MCT) inhibitor. Exhibits antitumoral and antiangiogenic activity in gliomas <em>in vivo</em>; decreases glycolytic metabolism, migration, and invasion in U251 cells. Enhances the effect of antitumor agent temozolomide. Blocks lactate efflux from glioma cells and sensitizes cells to irradiation.
|
|
| BCC7995 | 2-MPPA |
|
Selective glutamate carboxypeptidase II (GCP II) inhibitor (IC50 = 90 nM). Selective for GCP II over NMDA, kainate and AMPA glutamate receptors and MMP-1, -2, -3, -7, -9, ACE and NEP metalloproteases. Antinociceptive in a rat model of neuropathic pain and protects against motor neuron death in familial amyotrophic lateral sclerosis mice. Orally bioavailable.
|
|
| BCC7996 | AS 2034178 |
|
Selective free fatty acid receptor 1 (FFA1/GPR40) agonist. Exhibits selectivity for GPR40 over GPR41, GPR43, GPR119, GPR120 and PPAR<span class='symbol'>γ</span>. Induces glucose-dependent insulin secretion in pancreatic MIN6 cells and <em>in vivo</em>. Enhances insulin sensitivity in a type 2 diabetes model <em>in vivo</em>. Orally available.
|
|
| BCC7997 | ML 786 dihydrochloride |
|
Potent Raf kinase inhibitor (IC50 values are 2.1, 2.5 and 4.2 nM for B-RafV600E, C-Raf and wild-type B-Raf respectively). Also inhibits Abl-1, DDR2, EPHA2 and RET tyrosine kinase activity. Inhibits pERK formation and attenuates tumor growth in melanoma cell xenografts expressing the B-RafV600E mutation in vivo. Orally bioavailable.
|
|
| BCC7998 | ABT |
|
Cytochrome P450 inhibitor. Inhibits synthesis of the eicosanoid 20-hydroxyeicosatetraenoic acid (20-HETE). Reduces intimal hyperplasia and vascular remodeling following endothelial injury in rat carotid arteries.
|
|